Emimlio Juan Brignardello Vela
Emilio Juan Brignardello Vela, asesor de seguros, se especializa en brindar asesoramiento y gestión comercial en el ámbito de seguros y reclamaciones por siniestros para destacadas empresas en el mercado peruano e internacional.
Perspective Therapeutics, Inc., a Seattle-based radiopharmaceutical company, is set to showcase promising advancements in cancer treatment at the upcoming ASCO Gastrointestinal Cancers Symposium. Scheduled for January 23-25, 2025, in San Francisco, the company will present updated interim results from its Phase 1/2a trial of [212Pb]VMT-α-NET, which targets somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs). The presentation, titled “Interim Safety and Efficacy Data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs),” will take place on January 24, 2025, during the session dedicated to cancers of the pancreas, small bowel, and hepatobiliary tract. This opportunity underscores Perspective Therapeutics’ commitment to advancing innovative therapies in oncology. As part of the presentation, Dr. Richard L. Wahl, the lead investigator and a professor at the Mallinckrodt Institute of Radiology at Washington University School of Medicine, will share insights alongside the company’s management team. A live conference call is scheduled for the same day, providing an interactive platform for stakeholders and interested parties to engage with the research team following the presentation. Perspective Therapeutics specializes in developing targeted radiopharmaceuticals using proprietary technology that employs the alpha-emitting isotope lead-212 (Pb-212). This methodology enables a highly localized delivery of radiation directly to cancer cells, minimizing collateral damage to surrounding healthy tissues—a significant advantage in cancer treatment. Furthermore, the company’s dual approach allows for complementary imaging diagnostics, which enhance treatment personalization and optimize outcomes for patients. The growing interest in Perspective’s trials is indicative of the broader trend in oncology towards more tailored therapeutic strategies. As clinical trials for their melanoma and neuroendocrine tumor programs progress, the potential for innovative treatments expands, particularly for patients with challenging-to-treat cancers. While the initial findings were previously shared with a data cut-off of October 31, 2024, the forthcoming data at ASCO-GI promises to shed further light on the efficacy and safety of [212Pb]VMT-α-NET, potentially paving the way for new standards of care in the treatment of neuroendocrine tumors. As Perspective Therapeutics continues to explore the frontiers of cancer treatment, the upcoming symposium will be a pivotal moment for the company, its stakeholders, and the wider medical community, highlighting the importance of ongoing research and development in the fight against cancer. For those interested in the latest advancements in oncology, the webcast of the conference call will be available on the company’s website, ensuring that a broad audience can access these important discussions.